What are beractant and survanta, and are they the same drug?
Beractant and Survanta are both brand names of exogenous (artificial) lung surfactant used to help premature babies breathe when their lungs are not producing enough surfactant. They are not the same product, but they are in the same treatment category and serve the same general purpose: improving oxygenation and reducing respiratory distress in neonates with surfactant deficiency.[1][2]
What do they treat, and which babies usually receive them?
They are used to treat neonatal respiratory distress syndrome (RDS) due to surfactant deficiency in preterm infants.[1][2] Clinicians typically use them soon after birth (timing and criteria depend on the hospital protocol and the infant’s gestational age/clinical condition).[1][2]
How are they given?
Both are given as an intratracheal (through the airway) dose using a technique for delivering surfactant directly into the lungs. The dosing schedule and repeat doses depend on the specific product and the infant’s response.[1][2]
What outcomes and risks are associated with surfactant therapy?
Surfactant replacement can improve lung function and oxygenation in infants with RDS. Like other intensive neonatal therapies, it can also be associated with procedure-related risks because it requires airway administration (for example, complications related to the intubation/delivery process) and potential short-term side effects. The specific risk profile and expected adverse events are described in each product’s prescribing information.[1][2]
Are there differences between beractant and Survanta (ingredients, dosing, or labeling)?
They are different commercial surfactant products, with product-specific labeling for composition, dosing instructions, and indications. Even when two drugs treat the same condition, they may have different administration details and package insert recommendations.[1][2]
Where can I find the official prescribing information?
The most reliable source for dosing, indications, contraindications, and adverse reactions is the product’s FDA-approved prescribing information (package insert).[1][2]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018560
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019654